Abstracts tagged "COVID-19"

Abstract Number: 1598 • ACR Convergence 2021
Trends in Medication Interruptions and Associations with Disease Flares During a Public Health Crisis: Longitudinal Data from Patients with Autoimmune Rheumatic Diseases During the COVID-19 Pandemic
Tiffany Dharia¹, Michael George², SHILPA VENKATACHALAM³, Shubhasree Banerjee², Joshua Baker², David Curtis⁴, Maria I. Danila⁵, Kelly Gavigan⁴, Peter Merkel², Dianne Shaw⁶, Jeffrey Curtis⁷ and William Nowell⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Vasculitis Foundation, Kansas City, MO, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The COVID-19 pandemic has had substantial impact on the care of patients with autoimmune rheumatic diseases (ARDs), resulting in frequent medication interruptions early in…
Abstract Number: 1619 • ACR Convergence 2021
Where Do Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric COVID-19 Fit Under the Cytokine Storm Syndrome Umbrella?
Randy Cron and Daniel Reiff, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although COVID-19 has been less severe in the pediatric population, with cases more likely to be mild or asymptomatic, there remains a proportion of…
Abstract Number: 0085 • ACR Convergence 2021
Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
Naomi Patel¹, Kristin D'Silva¹, Tiffany Hsu², Michael Di Iorio³, Xiaoqing Fu¹, Claire Cook⁴, Lauren Prisco⁵, Lily Martin⁶, Kathleen Vanni⁶, Alessandra Zaccardelli⁶, Yuqing Zhang⁷, Jeffrey Sparks⁶ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with immune-mediated diseases have similar risk of severe COVID-19 versus the general population but CD20 inhibitor users may be at increased risk of…
Abstract Number: 0103 • ACR Convergence 2021
Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
Laura Boekel¹, Femke Hooijberg¹, Erik Vogelzang², Maureen Leeuw¹, Sadaf Atiqi¹, Ronald van Vollenhoven³, Alexandre Voskuyl², Irene van der Horst-Bruinsma², Willem Lems¹, Taco Kuijpers², Marieke van Ham⁴, Luuk Wieske², Filip Eftimov², Maurice Steenhuis⁴, Sofie Keijzer⁴, Olvi Christianawati⁴, Floris Loeff⁴, Sander Tas⁵, Mike Nurmohamed⁶, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Retrospective studies have suggested that patients with rheumatic diseases may be at increased risk of severe COVID-19 related disease, and that this risk may…
Abstract Number: 0196 • ACR Convergence 2021
A Single Center, Double Blind, Randomized, Placebo-Controlled Trial of Anakinra in Adult Patients with Features of Cytokine Storm Syndrome in COVID-19
Lesley Jackson¹, Randy Cron¹, Nitasha Khullar², Christopher Chapleau³, Dongmei Sun⁴ and Winn Chatham¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama Birmingham, Birmingham, AL, ³UAB Pharmacy, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Some patients with COVID-19 develop respiratory distress and cytokine storm syndrome (CSS) which is characterized by hyperinflammation and may progress to multi-organ failure. Anakinra…
Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Daniel Magliulo¹, Stefanie Wade² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³BIDMC, Boston, MA
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
Abstract Number: 0964 • ACR Convergence 2021
Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases
Samuel Bitoun¹, Julien Henry², Christelle Vauloup Fellous³, Raphaele Seror⁴, Lina Mouna³, Candie Joly⁵, Delphine Desjardins⁵, Marie Bitu⁵, Roger Le Grand⁶, Anne-Marie Roque Afonso³ and Xavier Mariette⁷, ¹Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, ²Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Le Plessis Robinson, France, ³AP–HP, Hôpital Paul-Brousse, Department of Virology, University Paris Saclay, INSERM U1193,, Villejuif, France, ⁴Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184, FHU CARE FHU CARE, Le kremlin Bicetre, France, ⁵Paris-Saclay University, Inserm UMR 1184, FHU CARE, CEA, Le Kremlin Bicêtre, France, ⁶UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, Fontenay Aux Roses, France, ⁷Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…
Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Peter Izmirly¹, Mimi Kim², Marie Samanovic-Golden³, Ruth Fernandez Ruiz⁴, Sharon Ohana³, Alexis Engel⁵, Kristina Deonaraine¹, Mala Masson⁴, Xianhong Xie⁶, Amber Cornelius⁴, Ramin Herati⁴, Rebecca Haberman⁴, Jose Scher¹, Allison Guttmann³, Rebecca Blank⁷, Ben Plotz³, Mayce Haj-Ali⁴, Brittany Banbury³, Sara Stream⁸, Ghadeer Hasan³, Gary Ho³, Paula Rackoff⁷, Ashira Blazer³, H. Michael Belmont³, Amit Saxena³, Mark Mulligan⁴, Robert Clancy⁴ and Jill Buyon³, ¹New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Larchmont, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New Yok, NY, ⁶Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, ⁷New York University, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
Abstract Number: 1539 • ACR Convergence 2021
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Matas Orentas¹, Sonali Khandelwal², Michael Grant², Yanyu Zhang¹, Najia Shakoor² and Sobia Hassan¹, ¹RUMC, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Ana Medeiros-Ribeiro¹, Nadia Aikawa¹, Carla Gonçalves Schahin Saad¹, Emily Figueiredo Vieira Neves Yuki¹, Tatiana do Nascimento Pedrosa¹, Solange Fusco¹, Priscila Rojo¹, Rosa Pereira¹, Samuel Shinjo¹, Danieli Andrade¹, Percival Sampaio-Barros¹, Carolina Ribeiro¹, Giordano Deveza¹, Victor Adriano de Oliveira Martins¹, Clovis Artur Silva¹, Marta Lopes¹, Alberto Duarte¹, Leila Antonangelo¹, Ester Sabino¹, Esper Kallas¹, Sandra Gofinet Pasoto² and Eloisa Bonfá¹, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clinicas de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…
Abstract Number: 1599 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Rheumatic Conditions: A Qualitative Analysis of Perceived Risk and Decision Making
Courtney Wells¹, Guadalupe Torres², William Nowell³, Shilpa Venkatachalam³, Laura Stradford⁴, Kelly Gavigan³, Barbara Boyd-Floering⁵, Maria I. Danila⁶ and Kristine Carandang⁷, ¹University of Wisconsin-River Falls, White Bear Lake, MN, ²Patient Partner, Brooklyn Center, MN, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Whelton Virshup CreakyJoints Arthritis Clinic/ Global Healthy Living Foundation, Lake Worth, FL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Independent, San Diego, CA
Background/Purpose: The purpose of this qualitative study was to understand the concerns, behaviors, and experiences of adults with autoimmune rheumatic conditions, and to evaluate the…
Abstract Number: 1623 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada
Molly Dushnicky¹, Catherine Campbell¹, Karen Beattie¹, Roberta Berard², Tania Cellucci³, Mercedes Chan⁴, Tommy Gerschman⁵, Kristin Houghton⁵, Nicole Johnson⁶, Claire LeBlanc⁷, Lillian Lim⁸, Nadia Luca⁹, Paivi Miettunen⁶, Kimberly Morishita⁵, Jean-Philippe Proulx-Gauthier¹⁰, Dax Rumsey¹¹, Heinrike Schmeling⁶, Rosie Scuccimarri¹², Herman Tam¹³, Jaime Guzman¹⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Montreal Children's Hospital/McGill University Health Centre, Montréal, QC, Canada, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²McGill University/Montreal Children's Hospital, Montréal, QC, Canada, ¹³Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ¹⁴University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The COVID-19 pandemic has disrupted the delivery of routine healthcare and clinical research around the world. Several reports have shown an impact on rheumatology…
Abstract Number: L01 • ACR Convergence 2020
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Naomi Serling-Boyd¹, Kristin D'Silva¹, Tiffany Hsu², Xiaoqing Fu³, Rachel Wallwork⁴, April Jorge¹, Yuqing Zhang¹, Ellen Gravallese⁵, Hyon K. Choi⁶, Jeffrey Sparks⁷ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Mass General Hospital, Boston, MA, ⁴Johns Hopkins Hospital, Baltimore, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of poor outcomes from COVID-19 among rheumatic disease patients compared to the general population remains poorly understood. Filling this knowledge gap is…
Abstract Number: L02 • ACR Convergence 2020
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
Mark Yates¹, Satveer Mahil¹, Sinead Langan², Claudia De la cruz³, Paola diMeglio¹, Nick Dand¹, Zenas Yiu⁴, Kayleigh Mason⁴, Teresa Tsakok¹, Freya Meynall⁵, Helen McAteer⁶, John Weinman¹, Paolo Gisondi⁷, Luis Puig Sanz⁸, Richard Warren⁴, Francesca Capon¹, Jullien Denis⁹, Tiago Torres¹⁰, Chris Griffiths⁴, Jonathan Barker¹, Kimme Hyrich⁴, Andrew Cope¹, Ian Bruce⁴, Iain McInnes¹¹, Raj Sengupta¹², Helena Marzo-Ortega¹³, Matthew Brown¹, James Galloway¹ and Catherine Smith¹, ¹King's College London, London, United Kingdom, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University of Santiago, Santiago, Chile, ⁴University of Manchester, Manchester, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁶Psoriasis Association, London, United Kingdom, ⁷University of Verona, Verona, Italy, ⁸Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁹Hospices Civils de Lyon, Lyon, France, ¹⁰University of Porto, Porto, Portugal, ¹¹University of Glasgow, Glasgow, United Kingdom, ¹²Royal United Hospitals Bath, Bath, United Kingdom, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinician-reported registry data suggest that use of biologics in people with immune-mediated inflammatory diseases (IMIDs) is associated with a lower risk of adverse COVID-19…
Abstract Number: L05 • ACR Convergence 2020
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Kaleb Michaud¹, Sofia Pedro², Kristin Wipfler³, Ekta Agarwal⁴ and Patricia Katz⁵, ¹University of Nebraska Medical Center and Forward, the National Databank for Rheumatic Diseases, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Pfizer inc, Princeton Jct, NJ, ⁵UCSF, Mill Valley, CA
Background/Purpose: To understand medication and clinical care changes by patients with RA during the first 3 months (March through May 2020) of the COVID-19 pandemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].